Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer
The Prostate · 02.08.2026
DOI: 10.1002/pros.70230 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 02.08.2026. Verfasst von Saizo Fujimoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Upfront treatment intensification with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor has become a standard approach for metastatic hormone‐sensitive prostate cancer (mHSPC). However, prognosis remains poor for some patients despite second‐generation androgen receptor antagonist‐based doublet therapy. Although triplet therapy with darolutamide and docetaxel is available, its added clinical value over apalutamide‐ or enzalutamide‐based doublet therapy in real‐world practice remains unclear. Gleason pattern 5 (GP5) reflects aggressive tumor biology and may be relevant for treatment selection. We evaluated whether triplet therapy was associated with longer castration‐resistant prostate cancer‐free survival (CRPC‐FS) than apalutamide‐ or enzalutamide‐based doublet therapy in systemic treatment‐naïve mHSPC, with a particular focus on effect modification by GP5 status.
Methods
This retrospective multicenter cohort study used the ULTRA‐J multicenter collaborative database in Japan. We included systemic treatment‐naïve patients with mHSPC who received either doublet therapy with ADT plus apalutamide or enzalutamide, or triplet therapy with ADT, darolutamide, and docetaxel, between February 2018 and October 2024. The final analytic cohort consisted of 294 patients. Overlap weighting was used to reduce treatment‐selection bias. The primary endpoint was CRPC‐FS, and overall survival (OS) was assessed as a supportive endpoint. Progression‐free survival 2 (PFS2) and post‐CRPC docetaxel use were evaluated as exploratory post‐progression outcomes.
Results
The median follow‐up duration estimated using the reverse Kaplan‐Meier method was 18.0 months in the doublet group and 11.0 months in the triplet group. In the overlap weighting‐adjusted overall cohort, triplet therapy was associated with longer CRPC‐FS than doublet therapy (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.13–0.64; p = 0.002). A significant interaction was observed for GP5 status (p for interaction = 0.037). In the GP5‐positive subgroup, triplet therapy was associated with longer CRPC‐FS than doublet therapy (HR, 0.16; 95% CI, 0.06–0.42; p < 0.001), whereas no clear advantage of triplet therapy was observed in the GP5‐negative subgroup (HR, 1.85; 95% CI, 0.29–11.94; p = 0.52). No clear difference in OS was observed at the current follow‐up.
Conclusions
Triplet therapy was associated with longer CRPC‐FS than apalutamide‐ or enzalutamide‐based doublet therapy in systemic treatment‐naïve mHSPC. This association appeared more evident in patients with GP5‐positive disease. Given the shorter follow‐up in the triplet group, limited event numbers in subgroup and PFS2 analyses, and the nonrandomized nature of post‐CRPC treatment sequencing, these findings should be interpreted as hypothesis‐generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kindai University Hospital, Osaka, Japan.
- Department of Urology, Kindai University Nara Hospital, Nara, Japan.
- Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
- Department of Urology, Fujita Health University Hospital, Toyoake, Japan.
- Department of Urology, Kawasaki Medical School, Okayama, Japan.
ORCID-Profile: Saizo Fujimoto, Tsuyoshi Morita, Yutaka Yamamoto, Teruo Inamoto, Keita Tamura, Ryoichi Maenosono, Kiyoshi Takahara, Wataru Fukuokaya, Takahiro Kimura, Kazutoshi Fujita
Zitieren
APA
Fujimoto, S., Morita, T., Yamamoto, Y., Inamoto, T., Tamura, K., Yoshikawa, Y., Maenosono, R., Takeuchi, A., Takahara, K., Sugiyama, S., Komura, K., Yanagisawa, T., Fukuokaya, W., Kimura, T., & Fujita, K. (2026). Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70230
Vancouver
Fujimoto S, Morita T, Yamamoto Y, Inamoto T, Tamura K, Yoshikawa Y, et al. Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer. The Prostate. 2026. doi:10.1002/pros.70230
BibTeX
@article{Fujimoto2026,
author = {Fujimoto, Saizo and Morita, Tsuyoshi and Yamamoto, Yutaka and Inamoto, Teruo and Tamura, Keita and Yoshikawa, Yuki and Maenosono, Ryoichi and Takeuchi, Akihito and Takahara, Kiyoshi and Sugiyama, Seitetsu and Komura, Kazumasa and Yanagisawa, Takafumi and Fukuokaya, Wataru and Kimura, Takahiro and Fujita, Kazutoshi},
title = {Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone‐Sensitive Prostate Cancer},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70230}
}
EUVIMED